Send to

Choose Destination
Trends Mol Med. 2016 Jan;22(1):10-27. doi: 10.1016/j.molmed.2015.11.004. Epub 2015 Dec 12.

HIV-1 Eradication: Early Trials (and Tribulations).

Author information

Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address:


Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with access to treatment. However, ART does not lead to viral eradication owing to the persistence of replication-competent, unexpressed proviruses in long-lived cellular reservoirs. The potential for long-term drug toxicities and the lack of access to ART for most people living with HIV-1 infection have fueled scientific interest in understanding the nature of this latent reservoir. Exploration of HIV-1 persistence at the cellular and molecular level in resting memory CD4(+) T cells, the predominant viral reservoir in patients on ART, has uncovered potential strategies to reverse latency. We review recent advances in pharmacologically based 'shock and kill' HIV-1 eradication strategies, including comparative analysis of early clinical trials.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center